BioTrinity is attended by an ever-evolving international audience of c.850 delegates, comprising a mix of academic entrepreneurs, early stage and emerging life sciences R&D companies, funders & investors, big pharma teams, charities & research bodies, government, regulatory bodies, along with professional services and expert supporters to the industry.

What's New for 2026?

An R&D showcase of c.160 research updates streamed by stage, from Academic Posters to Pre-Seed, Seed, Series A & B stage

A dedicated one-day session showcasing opportunities for growth in international markets

A new 'match-making lunch' where early stage Founders & CEOs can meet with those that can provide support and guidance. Click here to find out more.​

A Big Pharma spotlight session

A focus on unlocking access to alternative sources of funding

View the event here.